Publication | Open Access

Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization

Medicinal ChemistryProperty-driven OptimizationMedicineDrug DiscoveryPharmacologyRational Drug DesignDrug DevelopmentMolecular DockingNovel TherapyBiomolecular Engineering